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Abstract 
We studied DNA methylation patterns of human papillomavirus (HPV) and tumor suppressor gene 
EPB41L3 in 148 anal and perianal biopsies to determine whether high levels of methylation would be 
associated with anal intraepithelial neoplasia (AIN). The most prevalent HPV type was HPV16, 
detected in 54% of the 30 benign biopsies, 33% of the 43 low-grade AIN (lgAIN), 82% of the 59 high 
grade AIN (hgAIN) and 4 of the 5 anal cancers. A methylation score was developed 
(0.561*HPV16me+0.439*EPB41L3) which had increasing values with severity of disease: the mean 
was 8.1% in benign, 13.2% in lgAIN, 22.3% in hgAIN and 49.3% in cancers (p<0.0001). The 
methylation score as a triage classifier at a cut-off of 8.8 gave a sensitivity of 90.6% (95% CI: 82.8, 
96.9), specificity of 50.7% (95% CI: 39.7, 61.6) and area under the curve of 0.82 (95% CI: 0.75–0.89) 
for separating hgAIN and cancer from benign and lgAIN biopsies. We conclude that methylation of 
HPV16 and EPB41L3 show highly significant association with increasing severity of AIN and cancer 
and may be useful as biomarkers in anal disease.  
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Introduction 
Human papillomavirus (HPV) infects a majority of people worldwide. Infection can occur at any age 
and can either be transient (usually resolving within a few years) or could be persistent and last for 
many decades [1]. High risk HPV (hrHPV) infection with types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 
58, 59, and 68 in epithelial basal cells, especially in certain sites such as the uterine cervix, vulva, 
vagina, anus, and tonsils is an important risk factor for the development of squamous cell cancers and 
adenocarcinomas [1, 2]. Natural infections can produce immunity to identical and related HPV types 
while vaccination with virus-like-particles elicits a strong humoral immune response that is an 
effective prophylaxis [3]. Persistence of hrHPV is a known strong risk factor for cervical cancer [4] 
and occurs in immunocompetent individuals but is more common in immunosuppressed patients, such 
as those infected by HIV [5]. The molecular mechanisms of transient versus persistent hrHPV 
infections have been only partially elucidated, but may involve differences in integration of the HPV 
genome into host DNA and DNA methylation [6, 7]. HPV DNA testing can identify almost all 
prevalent high-grade cervical intraepithelial neoplasia (CIN2 and CIN3) and cervical cancers in 
exfoliated cervical cells [8]. The test also has a good ability to predict incident disease several years in 
advance of clinical manifestation [9]. Recent widespread recognition that hrHPV testing is much more 
sensitive than cytology has driven implementation of primary hrHPV screening for cervical disease in 
many countries [8].  
 
Anal cancer has been growing in incidence in the past few decades, especially in women and also in 
men who have sex with men (MSM). Furthermore, anal cancer incidence is higher in HIV-positive 
MSM with approximately 100 cases compared to 25 cases per 100,000 in HIV-negative MSM [10, 
11] and only 1.5 per 100,000 in men in general in the UK [12]. Most anal cancers have been 
associated with HPV16, while other hrHPV types such as HPV18, HPV31 and HPV33 seem to play a 
much smaller role in anal cancer than in cervical cancer [13]. High-grade AIN (alternatively called 
anal HSIL) is also associated with hrHPV, especially HPV16, and multiple HPV types are often 
reported in HIV-positive men [14]. 
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Anal cytology sampling is problematic because anal folds may hide lesions and this has resulted in 
recommendations for more frequent sampling to compensate for poor sensitivity [15]. Normal, 
borderline or mildly dyskaryotic (also called ASCUS or LSIL) cytology is common in patients with 
hgAIN [16]. High-resolution anoscopy (HRA) is often used as the primary screening tool for high-risk 
populations in settings where resources can support such an intensive approach [17]. However, 
besides the high cost, using HRA to detect hgAIN has additional limitations such as a subjective 
result, availability of a trained HRA specialist and discomfort caused to the patient. Consequently, for 
decades, other methods of triage to biopsy and treatment have been actively sought to lessen the 
burden on the HRA clinics [18]. 
 
 DNA methylation testing of HPV and human genes has been validated as an accurate method for 
detection of CIN2 and CIN3 [19-22]. Levels of methylation increase over time in women with 
persistent HPV16 infection and are maximal in patients with cancer [23, 24]. We investigated if a 
similar methylation test might be usefully applied to people with anal disease based on our a priori 
hypothesis that high levels of methylation at genomic positions associated with hgCIN would also be 
associated with hgAIN. Here, we focus on the methylation of host gene EPB41L3 and the high risk 
viral types: HPV16, HPV18, HPV 31 and HPV 33. EPB41L3 (Erythrocyte Membrane Protein Band 
4.1 like 3) is a tumor suppressor gene that inhibits cell proliferation, promotes apoptosis and has been 
found to be highly methylated in many cancers such as lung, cervix, ovarian and breast [25-28]. 
 
 
Results 
There were 30 biopsies with <AIN, 43 lgAIN, 59 hgAIN and 5 cancers among the anal samples and 
11 biopsies of high-grade perianal lesions (Table 1). 
 
HPV genotyping 
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About a third (47/148) of samples were infected with multiple HPV types. 33% of anal biopsies with 
either <AIN, or lgAIN histopathology were not infected by hrHPV types while 53% and 33%, 
respectively, were HPV16 positive (Table 1). hgAIN anal and perianal biopsies were predominantly 
infected by HPV16 (83% and 91% respectively). A small proportion (9%) of anal and perianal hgAIN 
were infected with hrHPV types other than HPV16, i.e. 5 out of 59 of anal and 1 out of 11 of perianal 
biopsies. Also of note, all the perianal lesions were hrHPV positive. Only 9% of anal hgAIN biopsies 
were not infected by hrHPV (5/59). All cancers were hrHPV positive, four with HPV16 and one with 
HPV33. 
 
DNA methylation 
The DNAme levels of EPB41L3, HPV16L1 and HPV16L2 were significantly different between the 
four groups and increased with severity of the lesions (p<0.0001, Cuzick test for trend), but no 
significant differences in the likelihood ratios were found for methylation of HPV18, HPV31 and 
HPV33 and these latter markers were dropped from further analysis (Table 2). The univariable models 
(Table 2) investigating EPB41L3, HPV16 L1 and L2 regions were all highly significant (p<0.0001). 
The bivariable logistic regression using EPB41L3 and HPV16me was highly significant (p<0.0001, 
Table 2) as was each variable on its own. The linearly combined DNAme score was derived from the 
bivariable model and calculated as follows: 0.561*HPV16me+0.439*EPB41L3. For all three variables 
(EPB41L3, HPV16me and the DNAme score), there was a highly significant trend of increased 
methylation with disease progression (Cuzick tests for trend, p<0.0001). Figure 1 shows the 
methylation of EPB41L3, HPV16me and the DNAme score.  
 
The ROC curves comparing the methylation levels in the <AIN and lgAIN samples to the hgAIN and 
cancer cases (Figure 2) had an AUC of 0.712 (95% CI: 0.624, 0.801, p<0.0001) for EPB41L3, 0.781 
(95% CI: 0.705, 0.857, p<0.0001) for HPV16me and 0.821 (95% CI: 0.750, 0.892, p<0.0001) for the 
DNAme score. Figure 2 also shows the relative sensitivities and specificities of genotyping for 
HPV16 or genotyping for HPV16 and HPV18 combined. Supplementary Figure 1 shows ROC curves 
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comparing missing DNAme values imputed by MICE versus single imputation. The chart indicates 
that there was no statistically significant difference in our interpretations of the data using either the 
multiple or single imputed data.  
 
Sensitivity and specificity of the DNAme score to detect hgAIN and cancers and the proportion of 
positive samples identified by the DNAme score is shown in Table 3. At the 7.5 cut-off the DNAme 
score correctly identified all the cancers and 95% of the hgAIN, while correctly classifying 33% of 
the lgAIN and 50% of the <AIN biopsies. In comparison, sensitivity of HPV16 genotyping to detect 
hgAIN and cancer was 83% (95% CI: 73-92) and specificity was 59% (95% CI: 48-70).  
 
Supplementary figure 2 shows a scatter plot of methylation of EPB41L3 against HPV16me with the 
relationship having a weak Spearman correlation. We also investigated whether the DNAme score 
would be able to correctly identify the 11 high-grade perianal samples (Supplementary figure 3) using 
cut-offs obtained with anal samples. Ten of the cases were correctly identified at the cut-off 7.5 and 
nine at the cut-off 8.8. Finally, we stratified the methylation data by HPV16 positivity and found that 
most of the predictive methylation information was in the HPV16 infected patients, which 
demonstrated that DNA methylation provided triage information in addition to the information given 
by HPV16 genotyping. In contrast little if any diagnostic contribution was seen for methylation in the 
HPV16 negative group (Supplementary figure 4). 
 
Discussion 
The a priori hypothesis that high levels of methylation at genomic positions shown to be associated 
with hgCIN in our earlier research [19, 29] would also be associated with hgAIN has been confirmed, 
thus opening the way to methylation diagnostics of anal disease. Anal cytological abnormalities are 
poor predictors of hgAIN amongst HIV-positive patients [30]. Moreover, there is not a good 
correlation between cytology grades and histology grades. There are also substantial differences 
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between pathologists in interpreting anal histology. In our study, we used a single pathologist (MS) 
who had extensive experience in anal pathology for all histology and the diagnoses were backed up by 
p16 staining when indicated [31, 32]. Goldstone et al. showed that 20% of patients with normal anal 
cytology and more than 30% with borderline cytology had hgAIN [33]. HPV DNA testing as a 
primary anal screen has the advantage of greater sensitivity than cytology and has an advantage of 
lower costs than screening with high-resolution anoscopy. Another advantage of HPV screening is 
that anoscopy is a complex procedure with a need for extensive training of practitioners. However, the 
fundamental problem with HPV DNA testing that has precluded its widespread use in identifying anal 
precancer is poor specificity. For example, Salit et al [17] showed that 88% of their HIV+ patients 
were HPV DNA positive for carcinogenic types. The specificity of HPV testing can be partially 
rectified by focusing on HPV16, which is one of the most common types found in anal cancer [34-
37]. However, since HPV16 is not present in all anal cancers there is a good chance that high-risk 
progressive lesions will not be detected. In our study, we found that most AIN were positive for 
hrHPV DNA and the majority of hgAIN were positive for HPV16, with relatively few positive for 
other hrHPV types. However, only 4 of the 5 anal cancers were positive for HPV16, the other being 
positive for HPV33, which shows the limitation of relying on HPV16 genotyping triage.  
 
DNA methylation is a potential option that may offer greater improvements in triage specificity while 
retaining good sensitivity and importantly detect all the cancers. In our study, all of the anal cancers 
were positive (i.e. above the cut-off) for DNA methylation, similar to what has been generally 
observed for cervical cancer. The DNAme score we developed is a multi-biomarker panel composed 
of three CpG sites within the EPB41L3 gene and the late regions (L1 and L2) of HPV16. The AUC of 
the methylation score for separating <AIN and lgAIN from hgAIN and cancer was 0.82 (95% 
confidence interval: 0.75, 0.89, p<0.0001, Table 3). Studies have shown that cervical cancers have 
higher levels of methylation than CIN3 [20]. All the anal cancers in our study were highly methylated 
and quite well separated from the hgAIN. This suggests the possibility that DNA methylation may be 
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used to indicate AIN destined to progress to anal cancer from lesions that will regress or remain 
indolent [38-40].   
 
It is notable that the triage information for hgAIN and cancer provided by the methylation score was 
significantly higher only in HPV16 positive people (Supplementary figure 4); however, the cancer 
negative for HPV16 was strongly methylated (25%) for EPB41L3. These data demonstrate that DNA 
methylation provides significant diagnostic information for detecting hgAIN in addition to that 
provided by HPV16 genotyping and suggests that a methylation test may be used to detect essentially 
all the cancers. The methylation score in HPV16 negative people did not show a significant 
discriminating effect. However, we cannot be sure of the lack of value of methylation information in 
the HPV16 negative samples because the analysis was underpowered for this endpoint. These results 
indicate the need for larger studies and a search for more genes that could provide additional triage 
information in people infected with hrHPV types other than HPV16. 
 
A limitation of the study is that we used FFPE biopsies. Our results need to be replicated in an 
adequately powered study of exfoliated anal cells because in routine practice hrHPV positive patients 
would have methylation tests performed on exfoliated cells collected by a swab or similar device. 
This would allow efficient triage to HRA, thus reducing costs, anxiety and possible over-treatment of 
low risk people. Our study had incomplete information on HIV status and the small size of the HIV-
negative subset likely produced some ascertainment bias. Another limitation of our study is the use of 
patients (mostly MSM) recruited from two sites specializing in anal HPV-related disease in London. It 
remains to be seen if our results can be duplicated in other settings.  
 
We conclude that high levels of DNA methylation are associated with hgAIN and anal cancer. This 
finding should be further explored to better understand the biological mechanisms and the value of 
DNA methylation testing as a molecular triage of hrHPV positive individuals for high-resolution 
anoscopy screening. 
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Material and Methods 
Patients 
A set of anal and perianal biopsy specimens were obtained from 148 patients (116 men, 31 women, 
and 1 person of unrecorded gender) of whom 94 were HIV positive, 40 were HIV negative and 14 had 
not been tested for their HIV status (Supplementary Table 1). The formalin-fixed paraffin-embedded 
(FFPE) biopsies were retrieved from the archives of the Homerton University Hospital and St 
Bartholomew’s and the Royal London Hospital in London, UK, which are tertiary referral units where 
people with suspected hgAIN are referred for further management. Institutional approval (R&D 
number: GU1310) for the study was obtained prior to commencing any research work on the 
specimens.  
 
In patients undergoing HRA, biopsies were obtained from areas of clinical interest that exhibited 
acetowhite changes (regardless of vascular changes) on 5% acetic acid application. Most of the 
biopsies showed morphological changes varying from slight to severe which distinguished them from 
the surrounding non-acetowhite normal epithelium. The main clinical endpoint for all comparisons 
was the histology result. The biopsies were graded histopathologically using the AIN terminology 
[41] which is in general use in the UK, acknowledging that recent recommendations for terminology 
in the US distinguish between low grade squamous intraepithelial lesion (LSIL equivalent to AIN1) 
and HSIL (equivalent to AIN2 and AIN3). The histopathological diagnoses were based on expert 
review by one of our team (MS) who has worked on anal neoplasia for more than 10 years. Diagnostic 
adjudication of difficult AIN cases was assisted by p16 staining of tissue sections [42] using the 
following rule: if the p16 result was positive (diffuse staining), the higher diagnosis (hgAIN) was 
assigned and if p16 was negative (focal, sporadic and negative staining), the lower diagnosis (lgAIN) 
was assigned. However, some of the biopsies showed only presence of HPV, and other biopsies 
showed slight changes that did not fulfil the criteria for lgAIN or hgAIN. These evidently non-normal 
biopsies are assumed as benign and were graded as <AIN.  
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HPV genotyping  
We used H&E sections annotated by MS as a guide to dissect areas of interest on the corresponding 
four unstained 5m sections, as previously described [43]. If more than one lesion was present on a 
single section, we dissected the lesion with the highest grade. The dissected areas from the four 
sections were placed in the same tube. Dissected areas were deparaffinized using 80L of hexadecane 
followed by a 5-minute incubation at 56°C. One hundred microliters of universal extraction buffer 
containing 50mM Tris-HCl pH 8.0, 1mM EDTA and 0.05% SDS [44] was added to tissues along with 
10l of Proteinase K (QIAGEN) and incubated overnight at 56°C followed by a one-hour incubation 
at 90°C. The lower phase was then transferred to a new tube and stored at -20°C before PCR. 
 
The samples were tested using the PapType High Risk HPV Detection and Genotyping kit (PapType 
kit, Genera Biosystems Ltd) according to the manufacturer’s instructions. The kit is able to detect 13 
high-risk HPV types (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68) a possible high risk 
type (HPV66) and two low-risk types (HPV6 and HPV11). The PapType test was performed with 
10L of DNA in a final reaction volume of 20L with the addition of 2% Tween 20. The PCR 
reaction amplifies a variable region of the L1 gene of the HPV genome. A fragment of the human 
cardiac myosin light chain gene (MLC-1) was co-amplified in the same reaction vessel as a quality 
and quantity control. For simplicity, we categorized the samples into three HPV genotype groups 
independently of whether they were singly or multiply infected: those infected by (1) HPV16, (2) by 
any other high-risk types (including HPV66) and (3) those HPV negative or infected only by a low-
risk type (lrHPV). We did not combine HPV18 with HPV16 due to obvious differences in viral 
disease characteristics as noted in earlier studies [1, 45] and the fact that HPV18 does not seem to play 
such an important role in anal cancers [46]. 
 
Methylation assays 
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Bisulfite conversions on 20l of DNA extracts were done using EZ DNA Methylation Kit (Zymo 
Research, CA, USA) following the manufacturer’s instructions. DNA methylation (DNAme) was 
measured by pyrosequencing for human biomarker EPB41L3 and viral late genomic regions of HPV16 
(CpG sites in the L1 region: 6367, 6389 and L2 region: 4238, 4247, 4259, 4268, 4275) and HPV18 
(CpG sites in the L2 region: 4257, 4262, 4266, 4269, 4275, 4282), HPV31 (CpG sites in the L1 region: 
6352, 6354) and HPV33 (CpG sites in the L2 region: 5557, 5560, 5566 and 5572) as previously 
described [47]. Amplification of CpG sites were carried out using PyroMark PCR kits (QIAGEN, 
Germany) with 10ng of converted DNA in a 25L volume with final concentration of reagents of 1x 
for Coral Load and PyroMark mix, 0.2M of PCR primers. PCR cycling conditions were 15 minutes at 
94°C, followed by 45 cycles of 94°C, 54°C, 72°C each for 30 seconds and a final extension at 72°C for 
10 minutes. The PCR products were pyrosequenced using a PyroMark™Q96 ID (Qiagen) instrument 
as previously described [48]. All pyrosequencing runs included a negative control and positive controls 
of known methylation level (0%, 50% and 100%) to allow standardized direct comparisons between 
different primer sets. For each marker, we calculated the average methylation level by taking the mean 
of all CpG positions.  
 
Statistical methods 
Missing methylation values for HPV were imputed with the value of zero for any HPV negative 
sample. Missing methylation values for EPB41L3 and HPV positive samples were imputed using a 
median regression with age as a predictor and DNA methylation as an outcome. All statistical 
analyses were performed on the imputed data set [49]. Out of the 137 anal samples, six had missing 
methylation values for EPB41L3, 22 for HPV16L1, 31 for HPV16 L2, 5 for HPV18, 11 for HPV31 
and none for HPV33. Of the 11 perianal samples, 4 had missing values for HPV16L1, 1 for HPV16L2 
and 3 for HPV18. No value was missing for EPB41L3, HPV31 nor HPV33 (Supplementary table 2). 
Statistical analyses for the anal and perianal lesions were not combined. Spearman correlations were 
calculated between the markers. Since methylation values of HPV16L1 and HPV16L2 regions were 
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correlated (Spearman r=0.570, p<0.0001), a variable called HPV16me was created by taking the 
geometric mean of DNAme levels of HPV16L1 and HPV16L2.  
 
Univariable and bivariable logistic models were fitted for statistically significant genes with the 
outcome measures 0 = <AIN and lgAIN and 1 = hgAIN and cancer. The likelihood ratio (LR) χ2 
statistic and its corresponding p-value, as well as the odds ratios (OR) with 95% confidence intervals 
were estimated and reported. Performance of the markers were assessed univariably by the LR 2 test 
and the area under the curve (AUC) with 95% confidence intervals (CI) using the Delong method 
[50]. Sensitivity and specificity were estimated at selected cut-offs (i.e. cut-off values giving the same 
sensitivity as HPV16 genotyping as well as at 90% and 95% sensitivity).  
 
A combined DNAme score of EPB41L3 and HPV16me was computed as a linear predictor of the 
fitted bivariable logistic regression. Confidence intervals for difference in sensitivities and 
specificities between the DNAme score at different cut-offs and HPV16 genotyping was computed 
using 2000 stratified bootstrap replicates as recommended by Carpenter and Bithell [51]. Cuzick tests 
for trend were applied to EPB41L3, HPV16me and the DNAme score to test for significant changes of 
methylation between the groups (<AIN, lgAIN, hgAIN, and cancer).  
 
Multiple imputations analyses were performed to test whether the single imputation led to any bias 
[52]. We used the multivariable imputation by chained equations (MICE) procedure (Classification 
and Regression Trees, CART) [53] with m=100 multiple imputations [54]. Rubin's rules were used to 
combine the multiply imputed estimates [55]. Receiver operating characteristics (ROC) of the 
DNAme score and AUC (95% CI) were estimated for the 100 multiple imputations separately and for 
their average.  
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All p-values were two-sided with significance set at α <0.05. Analyses were undertaken using R 
statistical software version 3.3.1 [56]. 
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Figure legends 
 
Figure 1. Comparison of DNAme levels of EPB41L1, HPV16 and the DNAme score 
(0.561*HPV16+0.439*EPB41L3) in <AIN, lgAIN, hgAIN and cancer cases. Perianal samples are not 
included in this figure. The top of box represent the upper quartile, bottom the lower quartile and line 
19 
 
the median. The upper (lower) whisker extends to the largest (smallest) point that is not more than 
1.5x of the inter-quartile range from the upper (lower) quartile. All data points with a methylation 
value >0 are shown individually (black circle).  
Figure 2. Receiver operator characteristic and associated area under the curve (AUC) of DNAme of 
EPB41L3, HPV16 and the DNAme score. The DNAme score (solid line) performed significantly 
better than EPB41L3 (dotted line) or HPV16 methylation (dashed line) on their own. For comparison 
the circle represents the performance of HPV16 genotyping while the triangle represents the 
performance of combined genotyping for HPV16 or HPV18. 
 
 
Supplementary figure legends 
Supplementary figure 1. Receiver operator characteristic and area under the curve (AUC, 95% CI) of 
the DNAme score calculated from the single-imputed data set (black), 100 imputed data set (grey) and 
the average of the 100 imputations (blue).  
 
Supplementary figure 2. Scatterplot of HPV16 versus EPB41L3 DNA methylation stratified by 
histopathological diagnosis. 
 
Supplementary figure 3. Dot plot of the DNAme score (0.561*HPV16+0.439*EPB41L3) calculated 
for the 11 high-grade perianal samples.  
 
Supplementary figure 4. Forest plot of the DNAme score stratified by HPV16 positivity for detecting 
hgAIN and cancer.  
 
 
